IRIS UniCatt

Colafigli, Manuela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.236
EU - Europa 2.867
AS - Asia 2.043
SA - Sud America 387
AF - Africa 57
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 3
AN - Antartide 1
Totale 8.599
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.148
SG - Singapore 947
DE - Germania 883
CN - Cina 532
FR - Francia 437
SE - Svezia 367
PL - Polonia 330
BR - Brasile 305
UA - Ucraina 237
IT - Italia 199
VN - Vietnam 149
GB - Regno Unito 131
IE - Irlanda 101
IN - India 90
ID - Indonesia 65
TR - Turchia 56
FI - Finlandia 55
CA - Canada 47
HK - Hong Kong 41
RU - Federazione Russa 41
AR - Argentina 35
JP - Giappone 35
BD - Bangladesh 32
MX - Messico 26
ZA - Sudafrica 21
BE - Belgio 14
IQ - Iraq 13
VE - Venezuela 12
NL - Olanda 11
PH - Filippine 11
ES - Italia 10
MA - Marocco 10
LT - Lituania 9
CO - Colombia 8
IR - Iran 8
PK - Pakistan 8
AT - Austria 7
SA - Arabia Saudita 7
EC - Ecuador 6
IL - Israele 6
CZ - Repubblica Ceca 5
EG - Egitto 5
EU - Europa 5
JM - Giamaica 5
JO - Giordania 5
KE - Kenya 5
KZ - Kazakistan 5
PY - Paraguay 5
CL - Cile 4
DZ - Algeria 4
KR - Corea 4
PE - Perù 4
TN - Tunisia 4
UY - Uruguay 4
AL - Albania 3
BG - Bulgaria 3
BO - Bolivia 3
CH - Svizzera 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
GR - Grecia 3
PS - Palestinian Territory 3
QA - Qatar 3
AM - Armenia 2
AU - Australia 2
AZ - Azerbaigian 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
KG - Kirghizistan 2
MD - Moldavia 2
MY - Malesia 2
NI - Nicaragua 2
NO - Norvegia 2
NP - Nepal 2
PT - Portogallo 2
RS - Serbia 2
TW - Taiwan 2
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BW - Botswana 1
CY - Cipro 1
EE - Estonia 1
HU - Ungheria 1
IM - Isola di Man 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MM - Myanmar 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
Totale 8.595
Salva come PNG Salva come JPEG
Città #
Singapore 502
Chandler 469
Ashburn 362
Kraków 317
San Jose 255
Jacksonville 163
New York 152
San Mateo 120
Dublin 99
Nanjing 90
Beijing 89
Dearborn 73
Houston 66
Wilmington 63
Lauterbourg 61
Los Angeles 60
Jakarta 59
Ann Arbor 54
Milan 53
Ho Chi Minh City 47
Nürnberg 47
Boston 46
Lawrence 45
Cattolica 43
Dallas 42
Izmir 41
Redmond 41
Hanoi 38
Nanchang 37
Hong Kong 36
Woodbridge 32
Munich 31
Redwood City 29
Tokyo 29
Frankfurt am Main 28
Hefei 27
The Dalles 26
Lancaster 23
Orem 23
Bremen 21
Changsha 20
Moscow 20
Fairfield 19
Ottawa 19
Atlanta 18
Buffalo 17
Santa Clara 17
Seattle 17
São Paulo 17
University Park 17
Chicago 16
Shenyang 16
Princeton 15
Boardman 14
Brussels 14
Hebei 13
Johannesburg 13
Kunming 13
London 13
Guangzhou 12
Montreal 12
Mountain View 12
Brooklyn 11
Fremont 11
Marseille 11
Norwalk 11
San Francisco 11
Düsseldorf 10
Jinan 10
Leawood 10
Poplar 10
Rome 10
Shanghai 10
Augusta 9
Chennai 9
Falls Church 9
Hangzhou 9
Jiaxing 9
Toronto 9
Verona 9
Warsaw 9
Denver 8
Nuremberg 8
Paris 8
Portsmouth 8
Pune 8
Washington 8
Amsterdam 7
Da Nang 7
Manchester 7
Phoenix 7
Porto Alegre 7
Rio de Janeiro 7
Tianjin 7
Biên Hòa 6
Helsinki 6
Simi Valley 6
Zhengzhou 6
Amman 5
Ankara 5
Totale 4.501
Salva come PNG Salva come JPEG
Nome #
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 269
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 227
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 210
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 203
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 199
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 194
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 192
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 190
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 189
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 186
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 181
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 177
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 176
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 174
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 168
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 167
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 166
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 166
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 165
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 158
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 155
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 154
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 152
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 150
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 149
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 148
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 148
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 145
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group 144
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 143
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 142
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 142
Long term follow-up of Nevirapine-treated patients in a single centre cohort 139
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 139
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 139
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 139
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 138
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 138
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 137
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 136
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors 134
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 134
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 134
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 129
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine 121
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 120
Interpretation systems for genotypic drug resistance of HIV-1 118
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 117
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 116
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study 106
Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: a multicenter retrospective cohort study 105
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 101
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 100
Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort 99
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study 89
Survival in HIV-infected patients after a cancer diagnosis in the cART era: Results of an Italian multicenter study 87
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 82
Combining epidemiological and genetic networks signifies the importance of early treatment in HIV-1 transmission 76
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 75
Totale 8.677
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.233
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.233
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021106 0 0 0 0 0 0 0 0 0 0 91 15
2021/2022555 51 52 13 41 24 28 9 104 17 46 72 98
2022/20231.141 170 177 82 185 82 143 25 92 129 5 38 13
2023/2024570 19 151 9 59 23 169 17 4 6 9 69 35
2024/2025991 17 29 70 48 135 44 20 56 155 99 173 145
2025/20262.497 409 55 157 298 509 117 450 146 169 181 6 0
Totale 8.677